Aeglea BioTherapeutics Announces Publication Of 20 Week Data From Phase 1/2 And Open-Label Extension Studies Of Pegzilarginase For The Treatment Of Arginase 1 Deficiency In The Journal Of Inherited Metabolic Disease

  • George Diaz

Press/Media

Period14 Jul 2021

Media coverage

11

Media coverage